PA
MYGN icon

PharVision Advisers’s Myriad Genetics MYGN Stock Holding History

PharVision Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.9K Buy
+16,449
New +$74.7K 1.77% 24
2026
Q1 		– Sell
-58,497
Closed -$360K – 452
2025
Q4 		$360K Buy
+58,497
New +$424K 0.18% 168

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PharVision Advisers's MYGN Position: Q2 2026 in Review

PharVision Advisers opened a new position in Myriad Genetics (MYGN) in Q2 2026: 16,449 shares worth $93.9K. The stake represents 1.77% of the portfolio and ranks #24 among its holdings. This is a return to the name: PharVision Advisers previously reported a position in MYGN as recently as Q4 2025.

PharVision Advisers first reported a position in MYGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $360K in Q4 2025. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • PharVision Advisers held 16,449 shares of Myriad Genetics worth $93.9K as of Q2 2026.
  • Myriad Genetics was a new PharVision Advisers position in Q2 2026.
  • Myriad Genetics made up 1.77% of PharVision Advisers's portfolio in Q2 2026, its #24 holding.
  • PharVision Advisers first reported a position in Myriad Genetics in Q4 2025 and has held it in 2 quarters since.
  • PharVision Advisers's Myriad Genetics position peaked at $360K in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.